The prognostic value of tumor-associated macrophages detected by immunostaining in diffuse large B cell lymphoma: A meta-analysis

Abstract

BackgroundThe prognostic implication of tumor-associated macrophages (TAMs) in the microenvironment of diffuse large B cell lymphoma (DLBCL) remains controversial.MethodsA systematic and comprehensive search of relevant studies was performed in PubMed, Embase and Web of Science databases. The quality of the included studies was estimated using Newcastle-Ottawa Scale (NOS).ResultsTwenty-three studies containing a total of 2992 DLBCL patients were involved in this study. They were all high-quality studies scoring ≥ 6 points. High density of M2 TAMs in tumor microenvironment significantly associated with both advanced disease stage (OR= 1.937, 95% CI: 1.256-2.988, P = 0.003) and unfavorable overall survival (OS) (HR = 1.750, 95% CI: 1.188-2.579, P = 0.005) but not associated with poor progression free survival (PFS) (HR = 1.672, 95% CI: 0.864-3.237, P = 0.127) and international prognostic index (IPI) (OR= 1.705, 95% CI: 0.843-3.449, P = 0.138) in DLBCL patients. No significant correlation was observed between the density of CD68+ TAMs and disease stage (OR= 1.433, 95% CI: 0.656-3.130, P = 0.366), IPI (OR= 1.391, 95% CI: 0.573-3.379, P = 0.466), OS (HR=0.929, 95% CI: 0.607-1.422, P = 0.734) or PFS (HR= 0.756, 95% CI: 0.415-1.379, P = 0.362) in DLBCL patients.ConclusionThis meta-analysis demonstrated that high density of M2 TAMs in the tumor microenvironment was a robust predictor of adverse outcome for DLBCL patients.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO, identifier CRD42022343045.

Serum-Soluble CD163 Levels as a Prognostic Biomarker in Patients with Diffuse Large B-Cell Lymphoma Treated with Chemoimmunotherapy

“…In most studies, high CD163 expression was correlated with an inferior prognosis. Controversial findings, as well as significant heterogeneity, have been reported regarding the contribution of CD163 expression in non-Hodgkin’s lymphoma disease activity, specifically in DLBCL, mantle cell lymphoma, follicular lymphoma, and T lymphoma [ 44 , 45 ]. The majority of studies have compared CD163 and CD68 immunohistochemical staining intensity in tissue biopsy.…”

S100A8 is a prognostic signature and associated with immune response in diffuse large B-cell lymphoma

“…S100A8 could induce a pro-inflammatory response, including inflammatory cytokines and chemokines, and introduce the tumor-promoting effect and suppression of anti-tumor immune responses ( 14 , 19 ). Tumor-associated macrophages (TAMs) can have a spectrum of phenotypes and be associated with a poor prognosis ( 71 ), A meta-analysis demonstrated that the high abundance of M2 TAMs in TME might be related to an adverse clinical outcome for DLBCL patients ( 72 ). The interaction with S100A8 can influence several aspects of tumor biology, which is associated with immunosuppression and TME remodeling through driving the polarization of macrophages toward an M2-like phenotype.…”

Single-cell and spatial transcriptomics reveal a high glycolysis B cell and tumor-associated macrophages cluster correlated with poor prognosis and exhausted immune microenvironment in diffuse large B-cell lymphoma

“…Previous studies have implicated TAMs in the tumorigenesis and invasive progression of DLBCL [ 22 – 24 ]. Meta-analyses revealed that high-density M2 TAMs within the tumor microenvironment are indicative of poorer OS in DLBCL [ 85 ]. Furthermore, Ma RY et al identified IFN_TAMs through scRNA-seq, characterized by heightened glycolytic activity, while its role in DLBCL remains unexplored.…”